Solutions for Targeted Protein Degradation
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that aims to selectively remove disease-causing proteins from cells. Traditional drug development often involves designing molecules that inhibit the activity of specific proteins, but TPD takes a different route in using cellular protein degradation mechanisms to facilitate protein elimination. One of the prominent strategies is the use of Proteolysis-Targeting Chimeras (PROTACs®).
PROTACs are bifunctional molecules composed of a ligand that binds to the target protein and another ligand that binds to an E3 ubiquitin ligase, which is an enzyme responsible for tagging proteins for degradation. By bringing the target protein and the E3 ligase into close proximity, PROTACs facilitate the ubiquitination and subsequent degradation of the target protein by the cellular proteasome.
Advantages:
PROTACs can target "undruggable" proteins;
The degradation process is not dependent on inhibiting the catalytic activity of the target protein;
PROTACs offer a prolonged and sustained effect on protein levels, due to molecule recycling;
Discover Products:
Proximity-based assays designed for rapid and sensitive quantitation of PROTAC screening and characterization against a specific E3 ligase and a specific protein of interest.
A large selection of available linkers and ligands for PROTAC development.
TPD Recombinant Target Proteins & E3 Ligases:
With or without tags, including Avi-tag, FLAG, His, Fc or biotin for binding assays or WB controls.
Resources:
